The acquisition of Italian specialty pharma company, Velit Biopharma (Velit), by UK-based specialty pharma business, Kelso Pharma (Kelso), announced on 13th November 2023, has now closed.
Kelso Pharma announces strategic partnerships with PharmaPath and Valpharma
Kelso Pharma, the growing UK-based specialty pharma business, has concluded two new collaboration agreements with pharmaceuticals companies, PharmaPath and Valpharma.
Kelso Pharma initiates European expansion with acquisition of Italian specialty pharma company, Velit Biopharma
Kelso Pharma (Kelso), the growing UK-based specialty pharma business, has taken its first step in its European expansion strategy by agreeing to acquire Italian specialty pharma company, Velit Biopharma (Velit).
Kelso Pharma announces two UK product acquisitions as growth continues
Kelso Pharma, the growing UK-based specialty pharma business, has concluded a deal to acquire two UK approved products, representing an exciting launch into the specialty of Dermatology with prescription medicines for the treatment of actinic keratoses and plaque psoriasis.
Kelso Pharma announces first product launch
Kelso Pharma, the growing UK based specialty pharma business, has announced its first product launch with the release to the UK prescription medicines market of Acepiro® (Acetylcysteine) 600mg effervescent tablets.
Kelso Pharma appoints UK Managing Director
Kelso Pharma, the growing UK based specialty pharma business, has appointed senior pharmaceutical executive, Mark Inker, as its first UK Managing Director.
Kelso Pharma appoints Life Sciences leader as Chairman
Kelso Pharma, the growing specialty pharma business, has appointed senior Life Sciences executive, Gordon Cameron OBE, as its Non-Executive Chairman. A senior executive with 25 years’ Board-level experience in private equity and plc listed businesses, Gordon has worked in the UK and US, primarily in biotech and pharmaceutical services including both contract research organisations (CRO) and contract development and manufacturing organisations (CDMO).
Apposite Capital-backed Kelso Pharma acquires Stirling Anglian Pharmaceuticals
Apposite Capital, the healthcare specialist private equity investor, and Kelso Pharma today (12th January 2022) announce the acquisition of Stirling Anglian Pharmaceuticals Limited. Kelso Pharma is headed by Dr Tom Stratford, previously CEO of Kyowa Kirin International (“KKI”), the European and US business arm of Kyowa Kirin, which purchased Scottish Borders based ProStrakan Group PLC in 2011. He is joined …
